Phase II trial of vindesine in advanced head and neck cancer.
Twenty-one patients with advanced epidermoid carcinoma of the head and neck region were treated with vindesine. Therapy was started at a dose of 3 mg/m2. Dose escalation by 0.5 mg/m2 weekly to a maximum of 4.0 mg/m2 was permitted when no toxicity was seen. Major dose-limiting toxic effects were neutropenia and peripheral neuropathy. Objective responses were seen in five patients: three partial responses lasting 2, 2, and 3 months, and two minor responses lasting 2 and 5 months.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D014747:Vinblastine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014751:Vindesine
D000970:Antineoplastic Agents; D014747:Vinblastine; D014751:Vindesine